Cell Source, Inc. financial data

Symbol
CLCS on OTC
Industry
Pharmaceutical Preparations
Location
57 West 57 Th Street, Suite 400, New York, NY
State of incorporation
Nevada
Fiscal year end
December 31
Former names
TICKET TO SEE, INC. (to 6/26/2014)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -101 % +1.06%
Return On Equity 31.4 % -23.7%
Return On Assets -2.16K % -33.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41M shares +7.48%
Common Stock, Shares, Outstanding 41.9M shares +9.9%
Entity Public Float 18M USD -60.7%
Common Stock, Value, Issued 41.9K USD +9.9%
Weighted Average Number of Shares Outstanding, Basic 41M shares +10.2%
Weighted Average Number of Shares Outstanding, Diluted 41M shares +10.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.94M USD +52.2%
General and Administrative Expense 2.14M USD -22.3%
Operating Income (Loss) -4.34M USD +1.67%
Nonoperating Income (Expense) -816K USD +26.7%
Net Income (Loss) Attributable to Parent -5.15M USD +6.71%
Earnings Per Share, Basic -0.16 USD/shares +11.1%
Earnings Per Share, Diluted -0.16 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22K USD +747%
Other Assets, Current 17.7K USD +8.46%
Assets 430K USD +18.6%
Accounts Payable, Current 1.75M USD +88.8%
Employee-related Liabilities, Current 9.75K USD 0%
Accrued Liabilities, Current 1.49M USD +35.4%
Liabilities 17.7M USD +15.9%
Retained Earnings (Accumulated Deficit) -44.4M USD -13.1%
Stockholders' Equity Attributable to Parent -17.3M USD -15.9%
Liabilities and Equity 430K USD +18.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -174K USD +43.8%
Net Cash Provided by (Used in) Financing Activities 152K USD -31%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 41.9M shares +9.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -22.2K USD +75.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 90.5K USD +312%
Deferred Tax Assets, Valuation Allowance 11.8M USD +14.4%
Deferred Tax Assets, Gross 11.8M USD +14.4%
Deferred Tax Assets, Operating Loss Carryforwards 10M USD +10.2%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 27.1M USD +11.4%
Share-based Payment Arrangement, Expense 289K USD -12.5%
Interest Expense 63.3K USD -54.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%